Skip to main content
OpenTrials
Completed

NCT Number: NCT01768403

Centralised Pan-Algerian Survey on the Undertreatment of Hypercholesterolemia

Centralized Pan-Algerian Survey on the undertreatment of hypercholesterolemia. The purpose of this study is to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the Third Joint European Task Force guidelines in the survey population.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hypercholesterolemia Arterial Occlusive Diseases Arteriosclerosis Atherosclerosis Cardiovascular Disease Cardiovascular Diseases Coronary Disease Coronary Heart Disease Diabetes Diabetes Mellitus Dyslipidemias Endocrine System Diseases Glucose Metabolism Disorders Heart Diseases Hyperlipidemias Hypertension Lipid Metabolism Disorders Metabolic Diseases Myocardial Ischemia Nutritional and Metabolic Diseases Peripheral Arterial Disease Peripheral Vascular Diseases Vascular Diseases

Age range

19 year and older

Sex eligibility

All sexes

Study type

Observational

About this study

Centralised Pan-Algerian Survey on the undertreatment of hypercholesterolemia.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject must provide informed consent and comply with the survey procedures.
  • Subject is on lipid lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks.

Exclusion criteria

  • Subjects who are unwilling or unable to provide informed consent.

Treatment and study plan

Primary outcomes

  1. Number and percentage of subjects achieving the LDL-C goals, according to the Third Joint European Task Force (TJETF) guidelines.

    Time frame: 24 weeks

Secondary outcomes

  1. Number and percentage of subjects achieving LDL-C goals according to the TJETF guidelines.

    Time frame: 24 weeks

    In the following sub-populations: - Patients with / or not with metabolic syndrome (according to NCEP III definition), - Primary/secondary prevention patients

  2. Number and percentage of subjects achieving LDL-C goals according to the NCEP ATP III/2004 updated NCEP ATP III and to the 2005 AFSSAPS guidelines

    Time frame: 24 weeks

    Overall and in the following sub-populations: Patients with/or without metabolic syndrome-Iary/IIary preven

  3. Number and percentage of subjects achieving LDL-C goals according to the : TJETF / NCEP ATP III and 2004 updated NCEP ATP III guidelines.

    Time frame: 24 weeks

    For the following sub-populations: Demographic variables, CV risk factors & Lipid-lowering agent class

  4. The association between achievement of LDL-C goals, according to the Third Joint European Task Force / NCEP ATP III / 2004 updated NCEP ATP III guidelines, and patient and physician variables, assessed by multivariate logistic regression models

    Time frame: 24 weeks

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Acronym: CEPHEUS

Important dates

Study start
2010
Primary completion
2011
Study completion
2011
First posted
Jan 15, 2013
Registry last updated
Jan 15, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.